🇺🇸 FDA

Intelligence Platform

Patents

Browse 24 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12290566

Dosing regimens and related compositions and methods

Apellis Pharmaceuticals, Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12251395

RNAS for complement inhibition

Apellis Pharmaceuticals, Inc. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11903994

Dosing regimens

Apellis Pharmaceuticals, Inc. · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844841

Dosing regimens and related compositions and methods

Apellis Pharmaceuticals, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11712460

Methods of treating chronic disorders with complement inhibitors

Apellis Pharmaceuticals, Inc. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11661441

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11510939

RNAs for complement inhibition

Apellis Pharmaceuticals, Inc. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407789

Cell-penetrating compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11338013

Combination therapy for C3 inhibition

Apellis Pharmaceuticals, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11291407

Detection of high risk drusen

Apellis Pharmaceuticals, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11292815

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and me

Apellis Pharmaceuticals, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11040107

Dosing regimens and related compositions and methods

Apellis Pharmaceuticals, Inc. · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11013782

Methods of treating chronic disorders with complement inhibitors

Apellis Pharmaceuticals, Inc. · Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11001610

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941184

Cell-penetrating compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10875893

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and me

Apellis Pharmaceuticals, Inc. · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10696718

Compstatin analogs for treatment of neuropathic pain

Apellis Pharmaceuticals, Inc. · Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10407466

Methods of selecting compstatin mimetics

Apellis Pharmaceuticals, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10308687

Cell-penetrating compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125171

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10039802

Methods of treating chronic disorders with complement inhibitors

Apellis Pharmaceuticals, Inc. · Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10035822

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and me

Apellis Pharmaceuticals, Inc. · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9421240

Compstatin analogs for treatment of neuropathic pain

Apellis Pharmaceuticals, Inc. · Granted Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8580735

Local complement inhibition for treatment of complement-mediated disorders

Apellis Pharmaceuticals, Inc. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted